CRISPR Therapeutics, a biopharmaceutical company focused on the breakthrough gene-editing technology CRISPR-Cas9, has raised $25 million in a series A investment from Versant Ventures.
http://ift.tt/1psmSat
http://ift.tt/1psmSat
Stem Cell Research News: News on Stem Cell Research continually updated from thousands of sources around from the B Media Network.
No comments:
Post a Comment